Pathological response to neoadjuvant chemotherapy for muscle‐invasive micropapillary bladder cancer

Micropapillary bladder cancer is a high grade variant with poor prognosis. There is no consensus about patients with micropapillary bladder cancer receiving neoadjuvant chemotherapy, but many suggest that radical cystectomy should not be delayed. Data from this study suggest that patients with micropapillary bladder cancer have a similar rate of response to neoadjuvant chemotherapy to that of patients with urothelial carcinoma. If these patients have pT0 disease, their survival is significantly improved at 2 years.

[1]  D. Wood.  Re: Novel Tumor Subgroups of Urothelial Carcinoma of the Bladder Defined by Integrated Genomic Analysis , 2014 .

[2]  D. Wood.  Re: Pathological Response to Neoadjuvant Chemotherapy for Muscle-Invasive Micropapillary Bladder Cancer , 2014 .

[3]  C. Taylor,et al.  Novel Tumor Subgroups of Urothelial Carcinoma of the Bladder Defined by Integrated Genomic Analysis , 2012, Clinical Cancer Research.

[4]  R. Wahlqvist,et al.  Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer. , 2012, European urology.

[5]  E. Messing,et al.  DO MIXED HISTOLOGICAL FEATURES AFFECT SURVIVAL BENEFIT FROM NEOADJUVANT PLATINUM‐BASED COMBINATION CHEMOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED BLADDER CANCER? , 2011, BJU international.

[6]  J. Witjes,et al.  Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. , 2011, European urology.

[7]  E. Messing,et al.  Do mixed histological features affect survival benefit from neoadjuvant platinum‐based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group‐Directed Intergroup Study (S8710) , 2010, BJU international.

[8]  Andrew H. Beck,et al.  Interobserver Reproducibility in the Diagnosis of Invasive Micropapillary Carcinoma of the Urinary Tract Among Urologic Pathologists , 2010, The American journal of surgical pathology.

[9]  R. Millikan,et al.  The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma. , 2006, The Journal of urology.

[10]  Nicholas J Vogelzang,et al.  Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. , 2003, The New England journal of medicine.

[11]  G. Griffiths.  Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists , 1999 .

[12]  S. Johansson,et al.  Micropapillary bladder carcinoma: a clinicopathological study of 20 cases. , 1999, The Journal of urology.

[13]  Mahul B. Amin,et al.  Micropapillary Variant of Transitional Cell Carcinoma of the Urinary Bladder Histologic Pattern Resembling Ovarian Papillary Serous Carcinoma , 1994, The American journal of surgical pathology.

[14]  M. Soloway.  Cis-diamminedichloroplatinum II in advanced urothelial cancer. , 1978, The Journal of urology.

[15]  C. Merrin.  Treatment of advanced bladder cancer with cis-diamminedichloroplatinum (II NSC 119875): a pilot study. , 1978, The Journal of urology.

[16]  C. Dinney,et al.  The impact of variant histology on the outcome of bladder cancer treated with curative intent. , 2009, Urologic oncology.